Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1530-1540
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1530
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1530
HVPG change | Intervention | Ref. |
No significant change in HVPG | Tadalafil 10 mg | Jagdish et al[1], 2021, Hept International |
N = 10, in seven patients, HVPG decreased and in three it increased but the decrease was not significant | Sildenafil 50 mg | Clemmesen et al[43], 2008, World J Gastroenterology |
Lowers portal pressure in the acute setting by about 20% | 75-100 mg of the phosphodiesterase-5-inhibitor udenafil | Kreisel et al[44], 2015, Dig Liver Dis |
Decreased HVPG in 4/5 patients | Vardenafil 10 mg | Deibert et al[45], 2006, Aliment Pharmacol Ther |
No effect on HVPG | Sildenafil | Tandon et al[46], 2010, Clin Gastroenterol Hepatol |
HVPG decrease from 10 mmHg to 7 mmHg (case report) | Sildenafil 20 mg bd | Bremer et al[47], 2007, J Med Case Rep |
HVPG decreased by 13%, and portal flow increased by 28% (case report) | Vardenafil | Deibert et al[48], 2018, World J Gastroenterology |
- Citation: Jagdish RK. Sexual dysfunctions and their treatment in liver diseases. World J Hepatol 2022; 14(8): 1530-1540
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1530.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1530